-+ 0.00%
-+ 0.00%
-+ 0.00%

Clarity Pharmaceuticals Reaches 383-Patient Target in Phase III Prostate Cancer Imaging Trial

PUBT·10/27/2026 01:23:09
Listen to the news
Clarity Pharmaceuticals Reaches 383-Patient Target in Phase III Prostate Cancer Imaging Trial
  • Clarity Pharmaceuticals has dosed its target of 383 participants in the Phase III CLARIFY prostate cancer imaging trial.
  • The trial evaluates 64Cu-SAR-bisPSMA’s sensitivity and specificity for detecting pelvic lymph node cancer using same-day and next-day imaging, with histopathology as reference.
  • Topline CLARIFY results are expected in the first half of 2027, alongside results from AMPLIFY, which studies recurrent prostate cancer.
  • Final CLARIFY results are intended to support a US FDA application for the imaging agent’s use before definitive prostate cancer treatment.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clarity Pharmaceuticals Ltd. published the original content used to generate this news brief on October 27, 2026, and is solely responsible for the information contained therein.